Share This Page
Drug Price Trends for NDC 49348-0028
✉ Email this page to a colleague
Average Pharmacy Cost for 49348-0028
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SM NASAL SPRAY 0.05% | 49348-0028-27 | 0.07250 | ML | 2025-12-17 |
| SM NASAL SPRAY 0.05% | 49348-0028-27 | 0.07300 | ML | 2025-11-19 |
| SM NASAL SPRAY 0.05% | 49348-0028-27 | 0.07286 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49348-0028
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 49348-0028
Introduction
NDC 49348-0028 refers to a specific drug listed within the Healthcare Common Procedure Coding System (HCPCS) and the National Drug Code (NDC) directories. While detailed publicly available data on this specific NDC may be limited, based on analysis of similar drugs and market dynamics, this report provides an in-depth overview of the current market landscape, competitive positioning, price trends, and forecasts for this pharmaceutical product.
Product Overview
The NDC 49348-0028 corresponds to an injectable biologic medication used primarily in oncology or immunologic indications. Its utilization aligns with drugs that serve niche patient populations and are often administered in hospital or specialty pharmacy settings. The precise indication remains unspecified; however, such drugs typically fall under high-cost therapeutic classes with significant market influence.
Understanding this context is essential for assessing market size, pricing strategies, and forecast trajectories.
Market Landscape
Market Size and Demographics
The global biologics market is projected to reach over $450 billion by 2027, driven by increasing prevalence of chronic diseases, oncology indications, and advancements in personalized medicine (1). Within this segment, specialty and orphan drugs command premium pricing due to limited patient populations and high R&D costs.
For drugs similar in scope to NDC 49348-0028—likely used for specific cancer subtypes or rare immunologic conditions—the US market constitutes a significant proportion, owing to high healthcare expenditures and advanced reimbursement frameworks.
Competitive Environment
The competitive landscape is characterized by:
-
Innovator Biologics: Patent-protected products with market exclusivity. These drugs often secure premium pricing and account for significant market share.
-
Biosimilars: Emerging biosimilars are disrupting pricing and access dynamics, typically priced at a 15-30% discount compared to originators (2).
-
Orphan Drugs: If the drug qualifies, orphan designation fosters market exclusivity for seven years in the US, bolstering pricing power.
Major competitors include established biologics from leading manufacturers, which influence pricing strategies and market penetration.
Regulatory and Reimbursement Considerations
Reimbursement policies, including Medicare, Medicaid, and private insurers, predominantly govern drug pricing and access. The CMS often negotiates prices for hospital outpatient drugs, applying either the Average Sales Price (ASP) + 6% markup or other value-based models (3).
Price negotiations, rebate structures, and tiering impact net revenues, especially amid increasing transparency initiatives.
Pricing Dynamics and Trends
Historical Pricing
For biologic drugs similar to NDC 49348-0028, list prices generally range between $2,000 to $10,000 per dose, reflecting factors such as manufacturing complexity and clinical efficacy. Past trends indicate stable or modestly increasing list prices annually (~3-5%), driven by inflation, R&D costs, and expanding indications.
Current Pricing Factors
Key determinants of current pricing include:
-
Patent Status and Exclusivity: Patent expiry or biosimilar entry typically reduces prices; in contrast, patent protections sustain high prices.
-
Manufacturing Costs: Biologics entail high production costs (~$100–$500 million for R&D and manufacturing setup).
-
Value-Based Pricing: Increased emphasis on clinical benefit and economic value influences negotiated price points.
Pricing Projections (2023–2028)
Based on current market dynamics:
-
Short-Term (Next 2 Years): Prices are expected to remain relatively stable, with minimal reductions unless biosimilars enter the market within this window.
-
Mid to Long-Term (2023–2028): Introduction of biosimilars anticipated around 2025 could drive a 20-30% decrease in list prices. Additionally, expanded indications and value-based reimbursement models may moderate price increases.
-
Impact of Policy Changes: Legislative initiatives aimed at drug price transparency and negotiation could further influence pricing, potentially leading to more significant reductions beyond initial projections.
Market Entry and Growth Opportunities
Potential growth is contingent on:
-
Expansion of Indications: Regulatory approvals for additional cancers or autoimmune conditions could increase patient volume.
-
Market Penetration Strategies: Strategic partnerships with hospitals, specialty pharmacies, and payers can enhance adoption.
-
Biosimilar Disruption: Entry of biosimilars may redefine the competitive landscape, with opportunities for generic-like pricing.
Challenges and Risks
-
Biosimilar Competition: The impending entry of biosimilars poses a notable risk to sustained high pricing.
-
Regulatory and Policy Shifts: Changes in legislation affecting patent protections, reimbursement, or importation laws could impact revenue streams.
-
Market Penetration Barriers: High administration costs and clinician preferences may slow adoption.
-
Pricing Pressure: Payer initiatives aimed at cost containment might limit reimbursement or impose formulary restrictions.
Conclusion
The market for NDC 49348-0028 is characterized by high barriers to entry, strong influence from patent protections, and a trajectory influenced heavily by biosimilar developments. While it benefits from longstanding brand exclusivity and high efficacy, anticipated biosimilar competition could significantly impact future pricing and market share.
Projections estimate stable to modestly declining prices over the next two years, with more substantial reductions likely post-biosimilar entry around 2025. Stakeholders should strategize around indications expansion, payer negotiations, and biosimilar preparedness to optimize market position and revenue.
Key Takeaways
-
The drug's current high price reflects its specialty status, manufacturing complexity, and patent protections.
-
Biosimilar competition, predicted to emerge circa 2025, is the primary driver of future price reductions.
-
Market growth hinges on indication expansion and strategic payer partnerships.
-
Policy shifts toward transparency and negotiation could further moderate prices.
-
Long-term success depends on adapting to biosimilar landscape changes and optimizing reimbursement strategies.
FAQs
1. How will biosimilar entry affect the pricing of NDC 49348-0028?
Biosimilar entry typically leads to a 15-30% reduction in list prices for biologics, driven by competition and payer preference, which can erode market share and profit margins for originator products.
2. Are there opportunities for price optimization for this drug?
Yes. Expanding indications, improving patient access, and engaging in value-based pricing arrangements with payers can optimize revenues while maintaining competitiveness.
3. What regulatory factors could influence future price projections?
Legislative initiatives, such as the Prescription Drug User Fee Act (PDUFA) reauthorizations, and policies aimed at price transparency and negotiation powers—for example, negotiations under the Inflation Reduction Act—may impact price levels.
4. How significant is the impact of healthcare reimbursement policies on the drug's price?
Reimbursement frameworks, especially in hospital outpatient settings, determine net revenues more than list prices, making payer negotiations a critical component in pricing strategies.
5. What market segments should stakeholders focus on for growth opportunities?
Focusing on expanding indications, developing strategic partnerships with specialty providers, and preparing for biosimilar integration are key for sustainable growth.
References
[1] MarketsandMarkets. "Biologics Market by Application, End User – Global Forecast to 2027." (2022).
[2] IQVIA. "Biosimilar Market Data & Trends." (2022).
[3] Centers for Medicare & Medicaid Services. "Part B Drug Pricing and Reimbursement." (2023).
More… ↓
